INTUITIVE SURGICAL INC

Intuitive Surgical insider trading shows a strategic buy‑sell balance, with executives buying at $77 and selling at $420—indicating confidence and liquidity planning.

Intuitive Surgical insider buys 531 shares—signaling confidence amid a low 52‑week price, rising social buzz, and potential market rebound.

Insider buys at Intuitive Surgical signal cautious optimism—531 shares for $457 each amid a 13.6% YTD drop, showing exec confidence in long‑term robotics growth.

Intuitive Surgical insider sales reveal strategic portfolio rebalancing, not distress – a smart entry point for long‑term investors in a robust robotics leader.

Insider selling by Intuitive Surgical’s SVP shows routine, Rule 10b5‑1‑planned trades, while European distribution gains and strong clinical data keep investors confident in steady growth.

Intuitive Surgical’s latest insider trades show routine liquidity management amid its European distribution expansion, boosting recurring revenue and growth prospects.

Intuitive Surgical’s insider trades reveal a disciplined, confidence‑driven strategy while the company’s robotic‑surgery platform delivers proven safety, clinical benefits, and growing global market potential.

Intuitive Surgical insider trades reveal strong exec confidence, minimal market impact, and strategic growth, highlighting opportunities for investors and health systems embracing robotic surgery.

Insider buy at Intuitive Surgical signals confidence amid high valuation; insider trades hint at future growth from European expansion and RSU‑based purchases.

Insider buying by Intuitive Surgical’s CFO signals confidence as the company expands its da‑Vinci and Ion robots into Europe, bolstering growth and market dominance.